Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography

European Journal of Nuclear Medicine

Volumn 26, Issue 11, 1999, Pages 1458-1464

  Leslie, William D ^a,b   Greenberg, Cheryl R ^a   Abrams, Douglas N ^a,b   Hobson, Douglas ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Dopamine D2 receptors; Huntington disease; Neurological illnesses; Single photon emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; EPIDEPRIDE; IODINE 123; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BRAIN TOMOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG UPTAKE; HUMAN; HUNTINGTON CHOREA; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC EXAMINATION; PHOTON EMISSION TOMOGRAPHY;

ADULT; BENZAMIDES; BRAIN; CASE-CONTROL STUDIES; CONTRAST MEDIA; CORPUS STRIATUM; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MIDDLE AGED; PYRROLIDINES; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032749550     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050479     Document Type: Article

References (48)

1. The Huntington Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington disease chromosomes. Cell 1993; 72: 971-983.
2. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington disease mutation. Engl J Med 1994; 330: 1401-1406.
3. Quarrell O. The neurobiology of Huntington disease. In: Harper PS, ed. Major problems in neurology. London: W.B. Saunders; 1991: 141-177.
4. Dom R, Malfroid M, Baro F. A cytometric study of the putamen in different types of Huntington chorea. Adv Neurol 1976; 1: 369-385.
5. Lange H, Thörner G, Hopf AV, Schröder KF. Morphometric studies of the neuropathological process in choreatic diseases. J Neurol Sci 1976; 28: 401-425.
6. Richfield EK, O'Brien CF, Eskin T, Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington disease. Neurosci Lett 1991; 132: 121-126.
7. 2 receptor binding in patients with Huntington disease and other choreas: a PET study. Brain 1995; 118: 689-696.
8. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington disease. Brain 1997; 120: 503-514.
9. 2 receptor binding in asymptomatic gene carders and patients with Huntington disease. Brain 1996; 119: 2085-2095.
10. 2 receptor imaging and measurement with SPET. Adv Neurol 1993; 60: 494-500.
11. Kung HF, Alavi A, Chang W, et al. In vivo SPET imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990; 31: 573-579.
12. 2 receptor and technetium-99m-HMPAO brain perfusion SPET in the evaluation of patients with and subjects at risk for Huntington disease. J Nucl Med 1993; 38: 1274-1281.
13. 2 receptors in the human brain. Eur J Pharmacol 1992; 223: 105-107.
14. 123I] epidepride single-photon emission tomography. Eur J Nucl Med 1997; 24: 483-487.
15. 2 receptor imaging. J Nucl Med 1996; 37: 1589-1591.
16. Folstein SE, Jensen B, Leigh JR, Folstein MF. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983; 5: 605-609.
17. Folstein MF, Folstein SE. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
18. 2 receptor imaging agent [abstract]. 1993, Prairie Provinces Chapter Society of Nuclear Medicine Meeting, Saskatoon, Canada.
19. Leslie WD, Borys A, McDonald D, Dupont JO, Peterdy AE. External reference markers for the correction of head rotation in brain single-photon emission tomography. Eur J Nucl Mod 1995; 22: 351-355.
20. Montemurro DG, Bruni JE. In: The human brain in dissection. Oxford: Oxford University Press; 1988.
21. Kuwert T, Gansladt T, Jansen P, et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption. J Comput Assist Tomogr 1992; 16: 789-794.
22. Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epide-pride-SPET: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 1997; 38: 1711-1717.
23. 18F-FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-434.
24. Garnett ES, Firnau G, Nahmias C, Carbotte R, Bartolucci G. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease. J Neurol Sci 1984; 65: 231-237.
25. Young AB, Penney JB, Starosta-Rubinstein S, et al. PET scan investigations of Huntington disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurology 1986; 20: 296-303.
26. Hayden MR, Martin WRW, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington disease. Neurol 1986; 36: 888-894.
27. Leblhuber F, Hoell K, Reisecker F, et al. Single photon emission computed tomography in Huntington's chorea. Brain 1989; 29: 337-339.
28. Nagel JS, Johnson KA, Ichise M, et al. Decreased iodine-123 IMP caudate nucleus uptake in patients with Huntington disease. Clin Nucl Med 1988; 13: 486-490.
29. Reid IC, Besson JAO, Best PV, Sharp PF, Gemmell HG, Smith FW. Imaging of cerebral blood flow markers in Huntington disease using single photon emission computed tomography. J Neurol Neurosurg Psychiatry 1988; 51: 1264-1268.
30. Smith FW, Gemmell HG, Sharp PF, Besson JAO. Technetium-99 m HMPAO imaging in patients with basal ganglia disease. Br J Radiol 1988; 61: 914-920.
31. Nagel JS, Ichise M, Holman BL. The scintigraphic evaluation of Huntington disease and other movement disorders using single photon emission computed tomography perfusion brain scans. Semin Nucl Med 1991; 21: 11-23.
32. Hasselbalch SG, Øberg, G, Sørensen SA, et al. Reduced regional cerebral blood flow in Huntington disease studied by SPET. J Neurol Neurosurg Psychiatry 1992; 55: 1018-1023.
33. Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington disease. N Engl J Med 1987; 316: 357-362.
34. Hayden MR, Jewitt J, Stoessl AJ, Clark C, Ammann W, Martin WRW. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington disease. Neurology 1987; 37: 1441-1447.
35. Grafton ST, Mazziotta JC, Phal JJ, et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington disease. Ann Neurol 1990; 28: 614-621.
36. Kuwert T, Lange HW, Boecker H, et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington disease. J Neurol 1993; 241: 31-36.
37. Young AB, Penney JB, Starosta-Rubinstein S, et al. Normal caudate glucose metabolism in persons at risk for Huntington disease. Arch Neurol 1987; 44: 254-257.
38. Bruyn RPM, Hageman G, Geelen JAG, et al. SPET, CT and MRI in a Turkish family with Huntington disease. Neuroradiology 1993; 35: 525-528.
39. Boecker H, Kuwert T, Langen K-J., et al. SPET and HMPAO compared to PET with FDG in Huntington disease. J Comput Assist Tomogr 1994; 18: 542-548.
40. 18F-dopa uptake by PET in cases of chorea with or without dementia. J Neurol Sci 1993; 115: 153-157.
41. 2 receptors with [I-123]epidepride [abstract]. J Nucl Med 1998; 39 (Suppl): 123P.
42. 2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. Eur J Nucl Med 1999; 26: 46-50.
43. Kuwert T, Lange HW, Langen K-J, Herzog H, Aulich A, Feinendegen LE. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease. Psychiatry Res 1989; 29: 361-362.
44. Kuwert T, Lange HW, Langen K-J, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990; 113: 1405-1423.
45. Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington disease. Neurology 1992; 42: 223-229.
46. Whitehouse PJ, Trifiletti RR, Jones BE, et al. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann Neurol 1985; 18: 202-210.
47. 1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994; 243: 249-255.
48. Hattori H, Takao T, Ito M, Nakano S, Okuno T, Mikawa H. Cerebellum and brain stem atrophy in a child with Huntington's chorea. Computerized Radiol 1984; 8: 53-56.